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Abstract
Objective To determine whether a next-generation se-
quencing (NGS) panel of 34 cancer-associated genes would
cost-effectively aid in the treatment selection for patients
with metastatic melanoma, compared with a single-site
BRAF V600 mutation test.
Methods A decision model was developed to estimate the
costs and health outcomes of the two test strategies. The
cost effectiveness of these two strategies was analyzed
from a payer perspective over a 2-year time horizon with
model parameters taken from the literature.
Results In the base case, the gene sequencing panel
strategy resulted in a cost of US$120,022 and 0.721 qual-
ity-adjusted life years (QALYs) per patient, whereas the
single-site mutation test strategy resulted in a cost of
US$128,965 and 0.704 QALYs. Thus, the gene sequencing
panel strategy cost US$8943 less per patient and increased
QALYs by 0.0174 per patient. Sensitivity analyses showed
that, compared with the single-site mutation test strategy,
the gene sequencing panel strategy had a 90.9 % chance of
having reduced costs and increased QALYs, with the cost
of the gene sequencing panel test having minimal effect on
the incremental cost.
Conclusion Compared with the single-site mutation test,
the use of an NGS panel of 34 cancer-associated genes as
an aid in selecting therapy for patients with metastatic
melanoma reduced costs and increased QALYs. If the
base-case results were applied to the 8900 patients diag-
nosed with metastatic melanoma in the USA each year, the
gene sequencing panel strategy could result in an annual
savings of US$79.6 million and a gain of 155 QALYs.
Key Points
Genetic tests of tumors are used to inform treatment
selection for patients with metastatic melanoma. A
gene sequencing panel test can interrogate mutations
in multiple cancer-associated genes, while a single-
site mutation test determines the genotype of a single
variant.
From a US health-care payer perspective, testing and
selecting first-line targeted treatment for metastatic
melanoma using a next-generation sequencing panel
of 34 cancer-associated genes can lower the medical
costs and increase the patient’s quality and length of
life, compared with a single-site mutation test. Thus,
the gene sequencing panel test merits consideration
in the clinical management of patients with
metastatic melanoma.
1 Introduction
Melanoma is one of the most common cancers in the USA,
with an estimated 76,690 newly diagnosed cases and 9480
deaths annually [1]. About 2–5 % of newly diagnosed
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melanomas present with metastatic disease [2]. Prior to
recently approved therapies, patients with metastatic me-
lanoma generally had a poor prognosis, with a median
survival time of 6–9 months and a 5-year survival of less
than 15 % [3, 4]. Newer therapies report improved survival
times [5–7].
For patients with metastatic melanoma, the National
Comprehensive Cancer Network (NCCN) recommends
systemic therapy, enrollment in a clinical trial, or best
supportive care [2]. Systemic therapy can improve patient
survival and includes immunotherapies and targeted
therapies. The approved immunotherapies are ipilimumab
for first-line treatment and pembrolizumab and nivolumab
for second-line treatment. Ipilimumab binds CTLA-4 (cy-
totoxic T lymphocyte-associated antigen 4), thereby
blocking the inhibition of cytotoxic T lymphocytes by
CTLA-4 and consequently enabling cytotoxic T lympho-
cytes to recognize and destroy cancer cells. Although ip-
ilimumab can elicit long-lasting antitumor effects, it has a
relatively low response rate (28 %) and can cause serious
adverse events [5]. Several targeted therapies have also
been approved for patients with metastatic melanoma [8].
For example, the BRAF kinase inhibitor vemurafenib is a
first-line treatment option for patients carrying a BRAF
V600E mutation. Clinical studies have also demonstrated
that patients with activating mutations in KIT may respond
to therapy with imatinib, an inhibitor of tyrosine kinase
receptors [9–11]. In addition, patients with other mutations
may be candidates for treatment with therapies approved
for use in tumors of different origins or newer therapies
that are being evaluated in clinical trials for metastatic
melanoma [12, 13].
Approved systemic therapies are costly—a course of
ipilimumab therapy, for example, can cost as much as
US$150,000 [14]—and no definitive predictive biomarkers
are available to identify which patients are most likely to
benefit from ipilimumab treatment. For targeted therapy
with BRAF or KIT inhibitors, patients who carry specific
tumor mutations are more likely to respond, and these
mutations can be identified by genetic tests prior to ini-
tiation of therapy. Using a genetic test to choose the most
appropriate drugs may not only help to direct patients to
appropriate therapies sooner but also save money by
avoiding therapies that are less likely to be effective.
The FDA has approved a companion single-site muta-
tion test for vemurafenib, the cobas 4800 BRAF V600
mutation test [15], which is a real-time polymerase chain
reaction (PCR) assay designed to detect the BRAF V600E
(T1799A) mutation. However, this test may not identify
some patients who are likely to respond to BRAF in-
hibitors—for example, patients who carry other BRAF
mutations such as V600K, V600E2, L597Q, L597S, and
K601E. Tumors harboring these BRAF mutations are likely
to respond to inhibitors of BRAF and MEK [mitogen-ac-
tivated protein (MAP)/extracellular signal-regulated kinase
(ERK) kinase] based on data from pre-clinical and indi-
vidual patient studies as well as from clinical trials [6, 16,
17]. Furthermore, the single-site BRAF mutation test does
not interrogate the KIT gene for mutations such as L576P
that respond to imatinib therapy [18].
Next-generation sequencing (NGS) provides a platform
for the simultaneous identification of mutations in multiple
genes that are known to harbor hotspot mutations in tu-
mors. The comprehensive molecular overview of the pa-
tient’s tumor should allow more informed therapy
decisions for genetically heterogeneous diseases such as
melanoma. Research-use-only and laboratory-developed
NGS tests are available to sequence multiple cancer-asso-
ciated genes. As an example, the laboratory-developed
OncoVantageTM gene sequencing panel test uses NGS to
interrogate the most commonly mutated exons in 34 can-
cer-associated genes, including BRAF, KIT, and other ge-
nes that can contain clinically actionable mutations in
melanoma tumors [13] (Supplementary Table 1). There-
fore, this test could be used to identify patients with KIT
mutations who may benefit from imatinib therapy, patients
with BRAF V600 mutations who may benefit from vemu-
rafinib, or patients with BRAF mutations not readily de-
tectable by the single-site mutation test (e.g. V600K,
V600E2, L597S and K601E) who may benefit from both
BRAF and MEK inhibitors.
However, which test scenario is the most cost-effective
method of helping to identify the optimal treatment for
patients with metastatic melanoma is unknown. In this
study, we used clinical study results to model the cost ef-
fectiveness of the 34-gene NGS panel test and the cobas
BRAF V600 single-site mutation test for guiding therapy
selection in patients with metastatic melanoma.
2 Methods
2.1 Model
The aim of this study was to compare the cost effectiveness
of two gene test strategies that guide the selection of
therapies for patients with metastatic melanoma. A
schematic of the decision tree for the two test-and-treat
strategies is shown in Fig. 1. One branch of the decision
tree starts with a 34-gene sequencing panel test and the
other the cobas BRAF V600 single-site mutation test.
Treatments in each strategy are based on the NCCN
guidelines for melanoma [2]. In both strategies, patients
who test positive for BRAF V600 mutations received ve-
murafenib. BRAF V600 mutations considered positive in-
cluded V600E and V600K for the single-site mutation test
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and V600E, V600E2, V600K, V600R, and V600D for the
gene sequencing panel. These BRAF V600 mutations were
sensitive to vemurafenib in cell culture studies [16], and
patients who test positive for these mutations responded to
vemurafenib in clinical trials [6, 19]. Patients who test
negative for BRAF V600 mutations by the single-site mu-
tation test received ipilimumab. Patients who test negative
for BRAF V600 mutations by the gene sequencing panel
received one of three therapies: (1) imatinib if they carried
KIT mutations, (2) ipilimumab if they carried no actionable
mutations, or (3) were enrolled in a clinical trial if they
carried other actionable mutations. Clinical trials that do
not enroll patients based on a genetic marker were not
included in the model because these trials would probably
affect the two strategies equally.
The possible health outcomes from these treatments
comprised three mutually exclusive states: progression-free
survival, progression, and death. Transitions between states
occurred at 3-month intervals over a 2-year time horizon.
In the partitioned survival model, patients entered the study
in the initial state of progression-free survival and at each
cycle, either remained in that state or transitioned to one of
the other two states. Patients could remain in the progres-
sion state or transition to the death state in subsequent
cycles.
2.2 Costs and Utilities
Costs for the tests were taken from the Medicare clinical
laboratory fee schedule [20] and Quest Diagnostics. Costs
for drugs were calculated using the average weighted price
(AWP) in the Redbook and dosages provided in the ve-
murafenib and ipilimumab prescribing information and the
Carvajal et al. [11] study. Since this cost-effectiveness
study was conducted from a payer’s perspective, the payer
would have no drug costs for the clinical trial, which would
be covered by the sponsoring pharmaceutical company.
Health utilities for progression-free survival, progression,
and death were taken from Beusterien et al. [21].
2.3 Distribution of Patient Populations
The proportion of patients who were BRAF V600 positive
was based on BRAF mutation analyses from 295 con-
secutive de-identified formalin-fixed, paraffin-embedded
(FFPE) tissue specimens submitted to Quest Diagnostics
for testing [22] and from 496 clinical trial patients reported
in the single-site mutation test package insert [15]. These
analyses were conducted using both the single-site muta-
tion test and Sanger sequencing, which detects more BRAF
V600 E/K mutations as well as other BRAF mutations (e.g.
Fig. 1 Schematic of the
decision tree (a) and partitioned
survival model (b). NGS next-
generation sequencing
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V600 R/G), and any drop-outs in the testing were not in-
cluded in the calculation. For this cost-effectiveness study,
NGS was assumed to be equivalent to the Sanger se-
quencing in both assay sensitivity and specificity.
In the base-case analysis, we assumed that among pa-
tients who test negative for BRAF V600 mutations, 10 %
were enrolled in clinical trials, 6.6 % received imatinib,
and 83.4 % received ipilimumab. Approximately 3–5 % of
adults with cancer in the USA join clinical trials [23]; since
patients with metastatic melanoma have a poor prognosis
and a limited choice of therapies, we assumed that 10 %
would be a reasonable base-case estimate for the propor-
tion of patients enrolled in clinical trials when they did not
carry a BRAF V600 mutation. The impact of this as-
sumption was investigated in the sensitivity analysis.
Since co-occurrence of BRAF and KIT mutations is rare
[11], we assumed that the rate of KIT mutations in the
BRAF negative patient population would be 6.6 % (27/
409)—an NGS analysis of tumors from 699 patients with
advanced melanoma found that 27 patients carried a KIT
mutation and 409 patients did not carry a BRAF mutation
[24].
2.4 Clinical Parameters for the Partitioned Survival
Models
Partitioned survival analysis uses empirical clinical data for
overall survival and progression-free survival to determine
the number of patients in the three states of the model [25,
26]. Estimates of progression-free survival (PPFS) and
overall survival (POS) were based on results from phase 3
clinical trials, with separate estimates for each 3 months
segment of the study. Specifically, the values for PPFS and
POS were taken from the midpoint of each 3-month interval
from the Kaplan–Meier survival curves reported in the
clinical trials of vemurafenib [6], ipilimumab [5], and
imatinib [11] (Supplementary Table 2). The total number
of patients in a particular cycle was then calculated as
(n 9 PPFS) in the progression-free state, as [n 9 (POS -
PPFS)] in the progression state, and as [n 9 (1 - POS)] in
the death state (where n was the initial number of patients).
For the outcome of patients enrolled in the clinical trials, it
was assumed that the average response would be the same
as that for ipilimumab therapy, the likely treatment in the
comparator arm of a clinical trial for patients who are not
eligible for vemurafenib therapy.
2.5 Base-Case Analysis
Base-case outcomes were total costs incurred by the payer
and QALYs, where both were calculated on a per-patient
basis over a time horizon of 2 years. Incremental costs,
incremental effectiveness, and incremental cost-effective-
ness ratio were calculated to compare the two test strate-
gies. Costs were discounted at 3 % per year [27].
Calculations of the base-case outcomes were done using
Microsoft Office Excel 2010.
The total costs comprised a one-time genetic test and the
sum of the drug costs incurred in all 3-monthly cycles over
2 years. For each cycle, the cost of the drugs was calcu-
lated by multiplying the cost of drugs per patient and the
number of patients eligible to receive therapy at the mid-
point of the cycle as estimated in the partitioned survival
models. For treatment with vemurafenib and imatinib, pa-
tients received medication as long as they remained in the
progression-free survival state. For ipilimumab therapy, we
used the FDA-approved regimen, which is the adminis-
tration of the drug every 3 weeks for a total of 4 doses. The
NCCN guidelines also allow the reinduction of ipilimumab
for patients who relapse after initial response or progress
after stable disease for more than 3 months if they did not
experience significant toxicity during prior ipilimumab
therapy [2]. And since Barzey et al. [28] reported that an
average of 7 % of the patients received 5.44 doses of the
drug, total costs for ipilimumab included both costs for the
eligible patients in the midpoint of the first cycle and ad-
ditional costs for re-induction.
The overall effectiveness was the sum of effectiveness
calculated for each of the 3-month cycles over 2 years. The
effectiveness in a specific cycle was calculated as the sum
of (1) the health utility for progression-free survival mul-
tiplied by the number of patients in the progression-free
survival state at the midpoint of the cycle and (2) the health
utility for progression multiplied by the number of patients
at the progression state at the midpoint of the cycle.
2.6 Sensitivity Analysis
The sensitivity of the calculated costs and effectiveness to
uncertainties in the parameter estimates was examined
using @Risk software (version 6.1, Palisade Corporation)
for Microsoft Office Excel 2010. The ranges for re-induc-
tion and health-state utilities were taken from Barzey et al.
[28]. The range of relative health outcomes for clinical
trials or ipilimumab therapy was set at ±50 % from the
base value, and the range of all other variables was set at
±25 % from the base values. A triangular distribution was
assumed for the defined ranges of all parameters. The
probabilistic sensitivity analysis was based on 5000 Monte
Carlo simulations to examine the effect of simultaneously
varying all variables in the defined ranges on incremental
cost and incremental effectiveness.
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3 Results
3.1 Base Case
The base-case analysis used the BRAF mutation frequency
observed in a study of melanoma samples submitted to a
large national testing laboratory [22] (0.429 by the gene
sequencing panel and 0.349 by the single-site mutation test;
Table 1). The single-site mutation test strategy and the
gene sequencing panel strategy resulted in a cost to payers
of US$128,965 and US$120,022 per patient, respectively,
over a 2-year time horizon (Table 2). Therefore, the gene
sequencing panel strategy was associated with a cost sav-
ings of US$8943 per patient over the single-site mutation
test strategy. The QALYs resulting from the single-site
mutation test strategy and the gene sequencing panel
strategy were 0.704 and 0.721 per patient, respectively,
over the same time horizon. Therefore, the gene sequenc-
ing panel strategy provided an incremental 0.0174 QALYs
over the single-site mutation test strategy. These results
suggest that the gene sequencing panel strategy is a
dominant (less expensive and more effective) strategy over
the single-site mutation test strategy for patients with
metastatic melanoma.
3.2 Sensitivity Analyses
Since a higher mutation frequency was observed when
screening melanoma patients for enrollment in a clinical
study of vemurafenib, we also examined cost-effectiveness
using the BRAF mutation frequencies reported in that
clinical trial [15] (0.541 test positives for the single-site
mutation test and 0.617 test positives for the gene se-
quencing panel). In this analysis, the gene sequencing
panel strategy was associated with a cost savings of
US$5888 and increased QALYs of 0.0157, compared with
the single-site mutation test strategy (Supplementary
Table 3). Thus, the gene sequencing panel strategy re-
mained dominant.
When the effects of uncertainties in the parameter esti-
mates on incremental costs were investigated in multi-
variable sensitivity analysis, the cost of ipilimumab had the
largest effect, followed by the proportion of patients who
test positive by the single-site mutation test, the cost of
Table 1 Model parameters and values tested in base-case and sensitivity analyses
Parameter Base-case Rangea References
Proportions of patients
BRAF mutation-positive by single-site mutation test 0.349 0.262–0.436 [22]
BRAF mutation-positive by gene sequencing panel 0.429 0.322–0.536 [22]b
Gene sequencing panel BRAF mutation-negatives and receiving imatinib 0.066 0.050–0.083 Assumption
Gene sequencing panel BRAF mutation-negatives and enrolled in clinical trials 0.1 0.075–0.125 Assumption
Reinduction of ipilimumab
Reinduction rate 7 % of patients 5 %–7 % [28]
Number of doses 5.44 4.35–5.76 [28]
Costs
Vemurafenib (3 months) US$39,063 US$29,297–48,829 [14]
Ipilimumab (4 doses) US$150,227 US $112,670–187,784 [14]
Imatinib (3 months) US$66,316 US$49,737–82,895 [14]
Single-site mutation test US$179 US$134–224 [20]
Gene sequencing panel test US$2400 US$1800–3000 Quest
diagnosticsc
Health state utilities
Progression free 0.8 0.64–0.96 [21]
Progression 0.52 0.42–0.62 [21]
Death 0 – –
Relative health outcomes of clinical trial versus ipilimumab therapy 1 0.5–1.5 Assumption
Cost discount 3 % per year – [27]
a The ranges for reinduction and health state utilities were from reference [28]; the upper and lower bounds were ±50 % of base values for
relative health outcomes of clinical trials versus ipilimumab therapy and ±25 % of base values for other variables
b Also assuming equivalency of next-generation sequencing and Sanger sequencing in the detection of mutations
c Expected costs for test will vary based on individual health plan and government payer rates and coverage policies
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vemurafenib, and the proportion of patients in clinical trials
(Fig. 2a). Compared with these variables, the cost of the
gene sequencing panel test and the single-site mutation test
had a much smaller effect on the incremental cost. Within
the defined ranges for all the variables, the gene sequencing
panel strategy was always associated with cost savings over
the single-site mutation test strategy. In addition, when the
proportion of patients in clinical trials was reduced from
10 % to zero (and correspondingly the proportion of pa-
tients receiving ipilimumab therapy was increased from
83.4 to 93.4 %), the gene sequencing panel strategy re-
mained associated with cost savings over the single-site
mutation test strategy: the cost savings was US$1035 when
no patients were enrolled in clinical trials (Supplementary
Fig. 1). Similarly, when the proportion of patients taking
imatinib was reduced from 6.6 % to zero, the gene se-
quencing panel strategy also remained associated with cost
savings over the single-site mutation test strategy: the cost
savings was US$7911 when no patients took imatinib
(Supplementary Fig. 2).
Since the cost of ipilimumab had the largest effect on
the incremental cost of the gene sequencing panel strategy
compared with the single-site mutation test strategy
(Fig. 2), we also examined the effect of patients opting for
a lower-cost alternative to ipilimumab therapy. As shown
in Supplementary Fig. 3, as the proportion of patients
opting for a lower-cost alternative therapy increased, the
cost saved by the gene sequencing panel strategy de-
creased. However, even if 30 % of patients opted for an
alternative therapy that cost only 30 % as much as ip-
ilimumab therapy, the gene sequencing panel strategy was
still cost saving (US$3859 saved per patient).
Multivariable sensitivity analysis of incremental effec-
tiveness revealed that the three variables with the greatest
effects were the relative health outcome from clinical trials
versus ipilimumab therapy, the proportion of patients who
Table 2 Base-case outcome
Strategy Cost
(US$/patient)
Incremental cost
(US$/patient)
Effect
(years/patient)
Incremental effect
(years/patient)
ICERa
Single-site mutation test 128,965 Reference 0.704 Reference Reference
Gene sequencing panel 120,022 -8943 0.721 0.0174 Dominant
a Incremental cost effectiveness ratio (US$ per quality-adjusted life year gained)
Fig. 2 Multivariable sensitivity
analysis for the gene sequencing
panel strategy compared with
the single-site mutation test
strategy. Tornado plots show
the effect of uncertainty of
model parameters on
incremental cost (a) and
incremental effectiveness (b).
The lower and upper bounds of
the variables are listed on either
side of the bars. In b, clinical
trial versus ipilimumab
indicates the relative health
outcome for clinical trial
therapy versus ipilimumab
therapy
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test BRAF V600 positive by the gene sequencing panel test,
and the proportion of patients who test positive by the
single-site mutation test (Fig. 2b). Within the defined range
of these three variables, the gene sequencing panel strategy
could increase the effectiveness of therapies by as much as
0.03 QALYs over the single-site mutation test strategy.
The other four variables shown in Fig. 2b (i.e. utility of
stable disease, percentage of patients taking imatinib,
percentage of patients enrolled in clinical trials, and utility
of disease progression) had a smaller effect on incremental
cost. Within the defined range, these variables also resulted
in higher QALYs from the gene sequencing panel strategy
than the single-site mutation test strategy.
In a probabilistic sensitivity analysis based on 5000
Monte Carlo simulations, the gene sequencing panel
strategy was almost always associated with lower cost than
the single-site mutation test strategy (Fig. 3). This analysis
also revealed that the gene sequencing panel strategy had
90.9 % chance of having increased QALYs compared with
the single-site mutation test strategy.
4 Discussion
The analysis in this study showed that testing patient tu-
mors with a 34-gene sequencing panel can lower the
medical costs and increase the patient’s quality of life
compared with a single-site mutation test. In the base case,
the gene sequencing panel strategy cost US$8943 less and
increased the QALYs by 0.0174 years per patient over a
2-year time horizon compared with the single-site mutation
test strategy. If these results were applied to the 8900 pa-
tients diagnosed with metastatic melanoma in the USA
each year, the gene sequencing panel strategy could result
in an annual savings of US$79.6 million and a gain of 155
QALYs. A sensitivity analysis demonstrated that the costs
of the genetic tests (both the gene sequencing panel test and
the single-site mutation test) had a minimal effect on the
incremental cost of the gene sequencing panel strategy over
the single-site mutation test strategy. Rather, the costs of
ipiliumab and vemurafenib were among the most important
parameters affecting the incremental cost. The incremental
gain in QALYs in the gene sequencing panel strategy was
primarily driven by the higher number of patients who
would test BRAF mutation positive. Modeling the uncer-
tainties of the parameters showed that the gene sequencing
panel strategy is most likely (i.e. 90.9 % probability) to
dominate the single-site mutation test strategy and thus
merits consideration in the clinical management of patients
with metastatic melanoma. Consistent with our model, the
European Medicines Agency review of vemurafenib con-
cluded that there was sufficient evidence to support clinical
benefit for mutations other than the single nucleotide
variant that results in a V600E substitution [29].
The gene sequencing panel test could help identify ad-
ditional patients who might benefit from first-line BRAF
inhibitor therapies; these patients would otherwise receive
less effective and more costly immunotherapy. In the base
case, the gene sequencing panel test identified 8 % more
patients with BRAF V600 mutations than did the single-site
mutation test (Table 1). Recent NGS analysis of melanoma
tumors has identified other BRAF mutations such as L597
mutations and the PAPSS1-BRAF fusion, which are sen-
sitive to BRAF and MEK inhibitors [17, 30]. Therefore, the
assumption that 8 % more actionable BRAF mutations will
be identified by the gene sequencing panel test than by the
single-site mutation test is likely to be an under estimate.
The gene sequencing panel test could also help identify
patients with other actionable mutations that respond to
therapies approved for use in tumors of different origins or
therapies under clinical development. For example, pa-
tients with a KIT mutation may be treated with imatinib
instead of immunotherapy, and a small-molecule MEK1/2
inhibitor has shown activity against melanomas with
NRAS-mutations present in 20 % of the patients [31]. And
the greater the difference in the mutation detection rate
between the two test strategies, the greater the cost effec-
tiveness of the gene sequencing panel strategy.
One limitation of this study is that we did not consider
non-drug medical costs. However, these non-drug medical
costs would most likely increase the incremental cost
Fig. 3 Probabilistic sensitivity analysis for the gene sequencing
panel strategy compared with the single-site mutation test strategy.
The cost-effectiveness plane shows the effect of simultaneously
varying all model parameters on incremental cost (vertical axis) and
incremental effectiveness (horizontal axis) in 5000 Monte Carlo
simulations. The base-case outcome is shown by a white cross
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savings of gene sequencing panel strategy over the single-
site mutation test strategy. This increase in the incremental
cost savings would be due to fewer patients in the gene
sequencing panel strategy receiving ipilimumab, which has
higher non-drug costs because it is administered intra-
venously and has a high rate of side effects, compared with
vemurafenib, which is taken orally and has a lower rate of
side effects. Side effects could also incur direct medical
cost for treatment in addition to non-drug medical costs and
thereby affect the relative cost effectiveness of the two test-
and-treat strategies.
Another limitation of our analysis is the uncertainty in
several model parameters. These include the proportion of
the BRAF mutation-positive patients detected by the gene
sequencing panel test; for this proportion we assumed that
the gene sequencing panel test and Sanger sequencing were
equally sensitive in the detection of BRAF mutations be-
cause a comparison of sequencing platforms showed a
perfect correlation between Sanger sequencing and NGS in
detecting other mutations in tumor biopsies [32]. Other
uncertain parameters include the relative health outcome of
patients enrolled in clinical trials in comparison with pa-
tients receiving ipilimumab therapy; we assumed that base-
case patients enrolled in clinical trials would have similar
outcomes to patients treated with ipilimumab therapy (the
likely treatment in the comparator arm of a clinical trial).
However, the sensitivity analyses suggest that the gene
sequencing panel strategy typically remained more cost
effective throughout the range of parameter values ex-
plored. Nevertheless, an EVPI (expected value of perfect
information) analysis would be valuable to identify areas
where additional information may help to reduce the
uncertainty with regard to the gene sequencing panel
strategy in comparison with the single-site mutation test
strategy.
A further limitation is that the decision model used in
our analysis reflects present guideline-supported patient
management; however, the rapid accumulation of various
levels of actionable evidence used by clinicians results in a
diversity of clinical practice that is not captured. For ex-
ample, we assumed that patients with BRAF or KIT mu-
tations would receive targeted therapies, but some of the
patients might receive immunotherapy or be enrolled in a
clinical trial; however, the magnitude of latter scenario is
difficult to define. Patients with BRAF V600E or V600K
mutations may also be treated with a combination of BRAF
and MEK inhibitors (e.g. dabrafenib and trametinib). The
more expensive combination therapy could affect incre-
mental cost of the gene sequencing panel strategy over the
single-site mutation test (e.g. incremental cost would be -
US$88 instead of -US$8943 if the combination therapy
costs twice as much as vemurafenib); note, however,
genotyping of tumors would use a different FDA-approved
companion diagnostic test (THxID BRAF assay from
bioMe´rieux) than the cobas 4800 BRAF V600 mutation
test used in our analysis [7]. In addition, our decision
model only considers the first-line therapies and does not
include treatment following progression. Future first-line
treatments of metastatic melanoma could affect the cost
effectiveness of gene sequencing panel strategy versus
single-site mutation test strategy.
We have taken advantage of empirical data available
from randomized clinical trials to estimate parameters in
the partitioned survival models. This should have allowed
us to obtain good approximate counts of patients at each
cycle, although results for the vemurafenib clinical trial
were based on the single-site mutation test and may not be
applicable to the gene sequencing panel test, because the
results from these two tests are not perfectly correlated. We
limited our analysis to a 2-year time horizon because
longer-term survival data have not been reported for ve-
murafenib; however, a longer time horizon would be of
interest. An alternative method would have been to esti-
mate transition probabilities from state to state in a Markov
model and extrapolate the analysis to a life-time horizon.
However, this alternative method is likely to introduce
more uncertainty than the analysis carried out here. We
believe that a 2-year time horizon is appropriate given the
low median survival time for patients with metastatic
melanoma. The validity of our parameter estimates is,
nevertheless, constrained by the clinical trials themselves,
and we note that clinical testing of imatinib in KIT muta-
tion carriers had a limited enrollment of only 24 patients
[11].
5 Conclusion
Using an NGS panel of 34 genes as an aid in informing
therapy decisions for metastatic melanoma is expected to
reduce costs and increase QALYs compared with the sin-
gle-gene, single-site mutation test. The advantage of se-
quencing multiple genes likely to contain functional
genetic alterations should further increase as evidence for
additional actionable mutations accumulates.
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